The first and only FDA-approved treatment for your patients diagnosed with CPT I, CACT, CPT II, VLCAD, TFP, or LCHAD in long-chain fatty acid oxidation disorders (LC-FAOD)

INDICATION: DOJOLVI is a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

Prescribe DOJOLVI using the Start Form

Dojolvi ultracare start form image

Complete the Start Form with your patient and fax it to 1-415-723-7474.

For additional support, you may also call our UltraCare Guides at 1-888-756-8657.

Open Start Form

Get help accessing DOJOLVI

ultracare website image

UltraCare® Patient Services provides assistance services to help patients gain access to DOJOLVI. These services are designed to help patients and caregivers:

  • Understand insurance coverage
  • Determine eligibility for Financial Assistance Programs and Patient Assistance Programs
  • Gain access to resources in the Patient Support Programs

Visit UltraCare® Patient Services to connect with our UltraCare Guides.

Visit UltraCare

Stay Informed

Sign up to receive more information and updates about DOJOLVI. (*Required fields)

(*Required fields)

By submitting this form, you agree to allow Ultragenyx and its agents to collect the information provided and to be contacted directly by an Ultragenyx representative. Your information will not be used for any other purpose than for a representative to respond to your information request or for us to send you other DOJOLVI updates if you have registered to receive them.

Ultragenyx will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Ultragenyx and its agents. Ultragenyx will only use your information in accordance with its Privacy Policy.

Important Safety Information

What are the possible side effects of DOJOLVI?

  • Feeding tube problems. Feeding tubes may not work as well or stop working over time when taking DOJOLVI. Do not use DOJOLVI in feeding tubes made of polyvinyl chloride (PVC), a solid plastic material. Monitor the feeding tube to make sure it is working properly.
  • Intestinal absorption problems in patients with pancreatic insufficiency. If you have pancreatic insufficiency, consult with your healthcare provider as it may affect how well DOJOLVI works.
  • The most common side effects of DOJOLVI are:
    • stomach (abdominal) pain
    • diarrhea
    • vomiting
    • nausea

These are not all the possible side effects of DOJOLVI. Call your healthcare provider for medical advice about side effects. You may report side effects to Ultragenyx Pharmaceutical Inc. at 1-888-756-8657 or FDA at 1-800-FDA-1088.

Before taking DOJOLVI, tell your healthcare provider about all of your medical conditions, including if you:

  • are pregnant or plan to become pregnant. It is not known if DOJOLVI will harm your unborn baby. Pregnancy Safety Study: There is a pregnancy safety study for women who take DOJOLVI during pregnancy. The purpose of this study is to collect information about your health and your baby’s health. You can talk to your healthcare provider or contact 1-888-756-8657 to enroll in this study or get more information.
  • are breastfeeding or plan to breastfeed. It is not known if DOJOLVI passes into breast milk. Talk to your healthcare provider about the best way to feed your baby if you take DOJOLVI.
  • are taking a pancreatic lipase inhibitor, such as orlistat, as it may affect how well DOJOLVI works.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I take DOJOLVI?

  • See the detailed “Instructions for Use” at the end of the Patient Information Leaflet for instructions about how to mix and take DOJOLVI by mouth in soft foods or drinks or how to mix and give DOJOLVI through feeding tubes.
  • Take DOJOLVI exactly as your healthcare provider tells you.
  • Your healthcare provider may start you on a low dose of DOJOLVI and slowly increase your dose to help avoid side effects. If you are taking another medium chain triglyceride (MCT) product, stop taking the MCT before starting DOJOLVI.

Please see full Prescribing Information, including the Patient Information Leaflet, for additional Important Safety Information.

What are the possible side effects of DOJOLVI?

  • Feeding tube problems. Feeding tubes may not work as well or stop working over time when taking DOJOLVI. Do not use DOJOLVI in feeding tubes made of polyvinyl chloride (PVC), a solid plastic material. Monitor the feeding tube to make sure it is working properly.
  • The most common side effects of DOJOLVI are:
    • stomach (abdominal) pain
    • diarrhea
    • vomiting
    • nausea

Important Safety Information